WO2019207724A1 - Dispositif de séparation de constituants du sang, procédé de séparation de constituants du sang et procédé d'analyse de constituants du sang - Google Patents

Dispositif de séparation de constituants du sang, procédé de séparation de constituants du sang et procédé d'analyse de constituants du sang Download PDF

Info

Publication number
WO2019207724A1
WO2019207724A1 PCT/JP2018/017040 JP2018017040W WO2019207724A1 WO 2019207724 A1 WO2019207724 A1 WO 2019207724A1 JP 2018017040 W JP2018017040 W JP 2018017040W WO 2019207724 A1 WO2019207724 A1 WO 2019207724A1
Authority
WO
WIPO (PCT)
Prior art keywords
flow path
blood
filter
separation device
plasma
Prior art date
Application number
PCT/JP2018/017040
Other languages
English (en)
Japanese (ja)
Inventor
遼 小林
慶治 三井
哲臣 高崎
百合香 越智
耕磨 林
久皇 鈴木
Original Assignee
株式会社ニコン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ニコン filed Critical 株式会社ニコン
Priority to PCT/JP2018/017040 priority Critical patent/WO2019207724A1/fr
Priority to JP2020515400A priority patent/JP6939988B2/ja
Publication of WO2019207724A1 publication Critical patent/WO2019207724A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers

Definitions

  • the present invention relates to a blood component separation device, a blood component separation method, and a blood component analysis method.
  • the blood cell component and the plasma component are usually separated and analyzed separately.
  • the method for separating the blood cell component and the plasma component include a centrifugal separation method and a method using a blood cell separation filter.
  • the centrifugal separation method the centrifugal operation is complicated.
  • a blood cell separation filter for example, Patent Document 1 describes a glass fiber filter for blood filtration and the like.
  • the conventional method using a blood cell separation filter cannot sufficiently prevent the mixing of plasma components into the blood cell fraction.
  • One embodiment of the present invention includes a first flow path including a first introduction port into which a solution containing blood cells and plasma is introduced, and a filter unit in which a filter for capturing blood cells is installed, and the first flow
  • a blood component separation device including a second flow path connected to the filter portion of the path.
  • the second flow path may have a second introduction port, and may intersect the first flow path at the filter portion of the first flow path.
  • One embodiment of the present invention is a method for separating blood components using the blood component separation device, wherein (a) a solution containing blood cells and plasma is introduced from the first inlet into the first. Introducing into the flow path, causing the filter to capture blood cells in the solution, and moving the plasma in the solution in the first flow path; and (b) from the first inlet or the second inlet. Introducing a hemolytic agent, hemolyzing blood cells in the filter, and moving blood cell components released by hemolysis in the second flow path.
  • One embodiment of the present invention is a method for analyzing blood components using the blood component separation device, wherein (a) a solution containing blood cells and plasma is introduced from the first inlet into the first. A step of introducing into the flow channel and causing the filter to capture blood cells in the solution; and (b) after the step (a), the cleaning liquid is supplied from the first introduction port or the second introduction port. A step of removing the plasma in the filter by introducing into the passage, and (c) after the step (b), introducing a hemolytic agent from the first inlet or the second inlet, and blood cells in the filter And (d) analyzing the blood cells hemolyzed in the step (c).
  • One embodiment of the present invention is a method for analyzing hemoglobin A1c, wherein (a) a filter for separating blood cells and plasma captures blood cells in a solution containing blood cells and plasma; and (b) ) After the step (a), passing the washing solution through the filter and removing the plasma in the filter; (c) after the step (b), introducing a hemolytic agent into the filter; And hemolyzing A1c in the blood cells hemolyzed in the step (c), and (d) analyzing the hemoglobin A1c in the blood cells hemolyzed in the step (c).
  • FIG. 1 shows an example of the structure of the pump parts P1 and P2 of the blood component separation device 700 of FIG.
  • (A)-(d) is sectional drawing explaining operation
  • Experimental example 2 it is a graph which shows the result of having evaluated the influence of the plasma content which has on the measured value of HbA1c.
  • FIG. 6 is a schematic diagram showing the structure of a blood component separation device used in Experimental Examples 3 to 7.
  • Experimental example 3 it is a graph which shows the result of having measured the plasma in a blood cell fraction.
  • Experimental example 4 it is a graph which shows the result of having measured the plasma in a blood cell fraction.
  • Experiment 5 it is a photograph of each blood component separation device after hemolyzing and collecting blood cells after washing the filter with 20 ⁇ L, 25 ⁇ L or 30 ⁇ L of washing solution.
  • Experimental Example 6 it is a graph which shows the result of having evaluated the reproducibility of the measured value of HbA1c.
  • Experimental Example 7 it is a graph which shows the result of having evaluated the reproducibility of the HbA1c measured value.
  • the present invention is connected to a first flow path that includes a first inlet and a filter section in which a filter that separates blood cells and plasma is installed, and to the filter section of the first flow path.
  • a blood component separation device including a second flow path.
  • FIG. 1 is a schematic diagram showing an example of a blood component separation device of the present embodiment.
  • the blood component separation device 100 includes a first channel 10, a second channel 20, a third channel 30, a plasma analyzer 50, and a blood cell analyzer 60.
  • the first flow path 10 has a first introduction port 12 and a filter unit 11.
  • the second flow path 20 and the third flow path 30 are connected to the filter part 11 of the first flow path 10 and intersect the first flow path 10 at the filter part 11.
  • the first flow path 10, the second flow path 20, and the third flow path 30 may be formed of, for example, a tube such as a glass tube or a resin tube, and a groove is formed between two bonded plates.
  • a flow path may be formed by forming.
  • the width and height of the first channel 10, the second channel 20, and the third channel 30 are not particularly limited, and may be arbitrarily selected according to the type of sample. For example, the width and height of these channels can be set to such a size that the sample can pass through, and examples thereof include 1 ⁇ m or more, 10 ⁇ m or more, 50 ⁇ m or more, 100 ⁇ m or more.
  • the widths of the first flow path 10, the second flow path 20, and the third flow path 30 may be the same or different.
  • the diameter of the first channel 10 can be 50 ⁇ m or more, 80 ⁇ m or more, 100 ⁇ m or more, and the like.
  • the upper limits of the width and height of these channels are not particularly limited, and may be appropriately selected according to the size of the blood component separation device. Examples of the upper limit values of the width and height of these channels include 100 mm or less, 50 mm or less, 10 mm or less, 5 m or less, 2 mm or less, and the like. An example is a width of about 0.5 to 2.0 mm and a height of about 0.2 mm to 2.0 mm.
  • the shapes of the first flow path 10, the second flow path 20, and the third flow path 30 are not particularly limited, and the cross section of the flow path may be circular or rectangular.
  • the first flow path 10 includes a first inlet 12, a filter unit 11, and a valve V1.
  • the first inlet 12 introduces a solution containing blood cells and plasma into the first flow path 10. Moreover, it may be used to introduce other samples, reagents, and the like.
  • the first inlet 12 may have a funnel shape so that the sample can be easily introduced.
  • the filter unit 11 is a part where a filter for capturing blood cells is installed in the flow path.
  • the filter that captures blood cells selectively captures blood cells in the blood and separates them from components other than blood cells in the blood, including plasma. Therefore, it is possible to separate blood cells and plasma in blood.
  • the filter is not particularly limited as long as it has a material and a structure capable of capturing blood cells and allowing plasma to pass through, and a known blood cell separation filter can be used.
  • Examples of the filter include a porous film and a glass fiber film.
  • Examples of the filter material include polypropylene, polyethylene, polyethylene terephthalate, polybutylene terephthalate, polystyrene, polyvinyl alcohol, urethane, acrylic, rayon, and glass.
  • the filter examples include, for example, a fiber in which the above-described material is integrated in a nonwoven fabric, a molded body such as an open-cell foam in which continuous pores are formed using the above-described material, and a substantially spherical fine particle formed from the above-described material.
  • a fiber in which the above-described material is integrated in a nonwoven fabric a molded body such as an open-cell foam in which continuous pores are formed using the above-described material, and a substantially spherical fine particle formed from the above-described material.
  • a fiber in which the above-described material is integrated in a nonwoven fabric
  • a molded body such as an open-cell foam in which continuous pores are formed using the above-described material
  • a substantially spherical fine particle formed from the above-described material are integrated so as to form a close-packed structure, or are integrally molded by sintering the accumulated material, or are formed by forming a through-hole in a film formed
  • the average pore diameter of the filter is not limited so long as it captures blood cells and does not inhibit the passage of plasma, and examples thereof include 2 to 10 ⁇ m or 3 to 8 ⁇ m.
  • the average pore diameter is measured by a bubble point test method (JIS K 3832), an actual measurement method using an enlarged image by an electron microscope, or the like.
  • the porosity of the filter is not particularly limited, and examples thereof include 20 to 97% and 30 to 95% in order to ensure a practical filtration time and maintain the filter stability.
  • the valve V1 is for controlling the first flow path 10 in an open state or a closed state.
  • the valve V ⁇ b> 1 is disposed on the opposite side of the first introduction port 12 with respect to the filter unit 11 in the first flow path 10.
  • bulb V1 are located in this order.
  • the first inlet 12 is on the upstream side of the first flow path 10
  • the valve portion V1 is on the downstream side.
  • the solution introduced from the first introduction port 12 passes through the filter unit 11 and flows toward the valve unit V1.
  • the structure of the valve V1 is not particularly limited, and any valve used for a fluid device or the like can be used.
  • the valve V ⁇ b> 1 is disposed in the vicinity of the downstream end of the filter unit 11.
  • the valve V1 and the filter unit 11 are preferably in contact with each other.
  • the distance between the end of the valve V1 and the end of the filter unit 11 is at most about several millimeters. Is preferred.
  • the distance between the end of the valve V1 and the end of the filter unit 11 is about 0 to 10 mm, and is about 0 to 5 mm.
  • the blood cell fraction hemolyzed by the hemolysis process described later can be efficiently collected via the second flow path 20 or the third flow path 30.
  • the blood component separation device of the present embodiment may be configured without the valve V1.
  • a valve may be provided between the first introduction port 12 and the filter unit 11.
  • the plasma analysis unit 50 is for analyzing the plasma that has passed through the filter unit 11.
  • the plasma analysis unit 50 can be configured to analyze any plasma component according to the purpose.
  • the plasma analysis unit 50 may be a glucose analysis unit.
  • the plasma analysis unit 50 analyzes total cholesterol, LDL, HDL, TG, UA, blood creatinine, albumin, total protein, ALT, AST, ⁇ GTP, BUN, K ion, Na ion, Ca ion, Cl ion, and the like. It may be a thing.
  • the plasma analysis unit 50 may analyze BV, HCV, CRP, cTnT, cTnI, BNP, H-FAB, CK-MB, IL-6, etc., and analyze tumor markers, miRNA, etc. You may do.
  • the plasma analysis unit 50 may analyze a single item, or may analyze a plurality of items.
  • the blood component separation device includes the plasma analysis unit 50, the plasma component separated by the filter unit 11 can be directly analyzed in the device. Since the plasma component is sent from the filter unit 11 to the plasma analysis unit 50 through the flow path on the blood component separation device, there is no risk of contamination or contamination of the apparatus, and simple plasma. Analysis of components becomes possible. In addition, since the plasma component can be measured directly from the separation of blood cell components, the loss of non-specific measurement objects is eliminated, the accuracy is improved, and the examination time is further shortened.
  • the blood component separation device of the present embodiment may be provided with a plasma analysis unit 50 and / or a plasma recovery unit.
  • the blood component separation device of the present embodiment may be configured to provide a plasma recovery unit instead of the plasma analysis unit 50 and recover the plasma that has passed through the filter unit 11.
  • the collected plasma may be analyzed manually or using a plasma analyzer or the like, and may be stored for later analysis.
  • it is good also as a structure which provides a plasma collection
  • FIG. the plasma that has been analyzed by the plasma analysis unit 50 can be collected by the plasma collection unit.
  • the first flow path 10 may further include a fluid control unit that controls the flow of fluid in the flow path.
  • a fluid control part is arrange
  • the filter unit 11 is disposed between the first introduction port 12 and the fluid control unit, the speed at which the sample introduced into the first flow path from the first introduction port 12 passes through the filter unit 11 is increased. It can be controlled by the fluid control unit.
  • the fluid control unit may employ any configuration used for controlling the flow of fluid in the flow path by a fluid device or the like. Examples of the fluid control unit include an intake port, a pump, and a valve connected to the intake pump.
  • the fluid moves in the axial direction of the flow path from upstream to downstream.
  • This direction may be referred to as the first direction or the axial direction of the first flow path.
  • the first direction is a direction from the first inlet 12 toward the filter unit 11, and when the valve V1 is provided, the first direction is a direction from the filter unit 11 toward the valve V1.
  • the first flow path 10 may further include a waste liquid recovery unit that recovers the cleaning liquid in a cleaning process described later.
  • the second flow path 20 is connected to the filter unit 11 of the first flow path 10 in a direction different from the axial direction of the first flow path 10.
  • the second flow path 20 intersects the first flow path 10 at the filter unit 11.
  • the second flow path 20, the second introduction port 22, and valves V ⁇ b> 2 a and V ⁇ b> 2 b disposed on both sides sandwiching the connecting portion between the first flow path 10 are provided.
  • the angle at which the second flow path 20 intersects the first flow path 10 is not particularly limited, and may be an arbitrary angle.
  • the second flow path 20 is orthogonal to the first flow path 10.
  • the second flow path 20 and the first flow path 10 are disposed on substantially the same plane. By arranging these flow paths on substantially the same plane, the blood component separation device can be miniaturized.
  • the second inlet 22 is used to introduce a reagent such as a hemolytic agent into the second flow path 20.
  • the second inlet 22 may have a funnel shape so that a reagent or the like can be easily introduced.
  • the second introduction port 22 may be configured to be connected to a chemical solution port or the like (not shown).
  • the valves V2a and V2b are for controlling the second flow path 20 to an open state or a closed state.
  • the structure of the valves V2a and V2b is not particularly limited, and any valve used for a fluid device or the like can be used. As an example, a valve similar to the above-described valve V1 may be employed.
  • the valves V2a and V2b are arranged in the vicinity of the filter unit 11 as an example. In order to reduce the dead volume, for example, the valves V2a and V2b are preferably in contact with the filter unit 11.
  • the distance between the ends of the valves V2a, V2b and the filter unit 11 is a few millimeters at most. It is preferable that it is a grade.
  • the distance between the ends of the valves V2a and V2b and the end of the filter unit 11 is about 0 to 10 mm, and is about 0 to 5 mm.
  • valve V2a By providing the valve V2a, the valve V2a is closed while the blood cell component and the plasma component are separated in the first flow path 10, and the valve V2a is released after the separation reaction between the blood cell component and the plasma component. It becomes possible. This is effective when a reagent is introduced into the second inlet 22 in advance. In addition, by providing the valve V2b, it is possible to retain a reagent or the like in the second flow path 20. This is effective when it takes time to react the components in the filter unit 11 with the reagents.
  • the side of the second flow path 20 opposite to the second introduction port 22 with respect to the filter unit 11 may be closed or opened. Alternatively, it may be connected to a waste liquid recovery unit or the like.
  • the fluid moves in a second direction different from the first direction.
  • the second direction is a direction different from the axial direction of the first flow path, and is the axial direction of the second flow path.
  • the second direction is a direction from the second introduction port 22 toward the filter unit 11.
  • the third flow path 30 is connected to the filter unit 11 of the first flow path 10 in a direction different from the axial direction of the first flow path 10.
  • the third flow path 30 intersects the first flow path 10 at the filter unit 11 at a position different from the second flow path 20.
  • the first introduction port 12, the connection portion with the second flow path 20, and the connection portion with the third flow path 30 are arranged in this order.
  • the connection part with the 1st inlet 12, the 3rd flow path 30, and the 2nd flow path 20 may be arrange
  • the third flow path 30 includes valves V3a and V3b that are arranged on both sides of the connection portion with the first flow path 10.
  • the angle at which the third flow path 30 intersects the first flow path 10 is not particularly limited, and can be any angle.
  • the second channel 20 and the third channel may intersect the first channel 10 at substantially the same angle.
  • the third flow path 30 is orthogonal to the first flow path 10.
  • the third flow path 30 is disposed on substantially the same plane as the first flow path 10 and the second flow path 20. By arranging these flow paths on substantially the same plane, the blood component separation device can be miniaturized.
  • the valves V3a and V3b are for controlling the third flow path 30 to an open state or a closed state.
  • the valves V3a and V3b are disposed on both sides of the connection portion with the first flow path 10.
  • the valve V3a, the connection portion with the first flow path 10, and the valve V3b are arranged in this order.
  • the structure of the valves V3a and V3b is not particularly limited, and any valve used for a fluid device or the like can be used. As an example, valves similar to the above-described valves V1, V2a, and V2b may be employed.
  • the valves V3a and V3b are arranged in the vicinity of the filter unit 11 as an example.
  • the valves V3a and V3b and the filter unit 11 are preferably in contact with each other.
  • the distance between the ends of the valves V3a, V3b and the filter unit 11 is a few millimeters at most. It is preferable that it is a grade.
  • the distance between the ends of the valves V3a and V3b and the end of the filter unit 11 is about 0 to 10 mm, and is about 0 to 5 mm.
  • the blood component separation device of the present embodiment may be configured not to provide the valves V3a and V3b, or may be configured to provide only one of the valves V3a and V3b.
  • the valve V3a By providing the valve V3a, the valve V3a is closed while the blood cell component and the plasma component are separated in the first flow path 10, and the valve V3a is released after the separation reaction between the blood cell component and the plasma component. It becomes possible.
  • the valve V3b it is possible to retain a reagent or the like in the third flow path 30. This is effective when it takes time to react the components in the filter unit 11 with the reagents.
  • the third flow path 30 is connected to the blood cell analysis unit 60.
  • the blood cell analyzer 60 is for analyzing the blood cells captured by the filter unit 11. As will be described later, the blood cells captured by the filter unit 11 are hemolyzed by a hemolyzing agent or the like, and are carried to the blood cell analysis unit 60 via the third flow path 30.
  • the blood cell analyzer 60 can be configured to analyze any blood cell component according to the purpose.
  • the blood cell analysis unit 60 may be configured to analyze hemoglobin A1c (HbA1c) (HbA1c measurement unit).
  • the blood cell analysis unit 60 includes a configuration for measuring HbA1c by a latex agglutination method.
  • the blood cell analyzer 60 may have a configuration for measuring the amount of hemoglobin.
  • the blood cell analyzer 60 may have a configuration for measuring the activity of erythrocyte enzymes, typified by glucose 6-phosphate dehydrogenase and pyruvate kinase.
  • the blood cell analysis unit 60 may analyze a single item, or may analyze a plurality of items. Since the blood component separation device includes the blood cell analysis unit 60, the blood cell component separated by the filter unit 11 can be directly analyzed in the device. Since the blood cell component is fed from the filter unit 11 to the blood cell analysis unit 60 via the flow path on the blood component separation device, there is no risk of contamination and the blood cell component can be easily analyzed. .
  • the blood component separation device of the present embodiment may include a blood cell analysis unit 60 and / or a blood cell collection unit.
  • the blood component separation device of the present embodiment may have a configuration in which a blood cell collection unit is provided instead of the blood cell analysis unit 60 and the blood cell component captured by the filter unit 11 and hemolyzed is collected.
  • the collected blood cell components may be analyzed using a manual operation, a blood cell analyzer (such as a HbA1c measuring device), or the like, or may be stored for later analysis. Moreover, it is good also as a structure which provides a blood cell collection
  • the third flow path 30 may further include a fluid control unit that controls the flow of fluid in the flow path. Since the third flow path 30 includes the fluid control unit, the flow of fluid from the filter unit 11 to the third flow path 30 can be controlled.
  • the fluid control unit may employ any configuration used for controlling the flow of fluid in the flow path by a fluid device or the like. Examples of the fluid control unit include an intake port, a pump, and a valve connected to the intake pump.
  • the other end of the third flow path 30 that is not connected to the blood cell analyzer 60 may be closed or open. Alternatively, it may be connected to a waste liquid recovery unit or the like.
  • the fluid moves in a third direction different from the first direction.
  • the third direction is the axial direction of the third flow path 30.
  • the third direction is a direction from the filter unit 11 toward the blood cell analysis unit 60 or the blood cell collection unit.
  • the second flow path 20 and the third flow path 30 may be substantially parallel. In this case, the second direction and the third direction are substantially the same.
  • the valve V1 is opened, and the valves V2a, V2b, V3a, V3b are closed.
  • a blood sample is introduced into the first channel 10 from the first inlet 12.
  • the blood sample is not particularly limited as long as it contains a blood cell component and a plasma component, and an example is a whole blood sample.
  • the blood sample may be a blood sample obtained by removing white blood cells and the like.
  • the blood sample introduced into the first flow path 10 from the first introduction port 12 passes through the filter unit 11. At this time, blood cells are selectively captured by the filter. Most of the plasma passes through the filter. Some plasma may remain on the filter.
  • the first flow path 10 includes a fluid control unit
  • the flow of the blood sample passing through the filter unit 11 may be controlled by the fluid control unit. By controlling the flow of the blood sample, the blood sample passing speed in the filter unit 11 can be shortened.
  • the plasma that has passed through the filter unit 11 is analyzed in the plasma analysis unit 50 connected to the first flow path 10.
  • the plasma may be recovered in the plasma recovery unit.
  • the washing solution is not particularly limited as long as it does not destroy blood cells, and a known cell washing solution or the like can be used.
  • the washing liquid include phosphate buffered saline (PBS), physiological saline, and the like.
  • PBS phosphate buffered saline
  • the flow of the cleaning liquid that passes through the filter unit 11 may be controlled by the fluid control unit.
  • the washing solution that has washed the filter unit may be collected by the plasma analysis unit 50, and if the first flow path 10 includes a plasma collection unit or a waste solution collection unit, they may be collected by these.
  • the above-described cleaning process may be performed by opening the valve V2a and introducing the cleaning liquid from the second introduction port 22.
  • the cleaning liquid introduced from the second introduction port 22 is introduced into the filter unit 11 via the second flow path 20.
  • the plasma remaining in the filter unit 11 can be removed by the washing liquid introduced into the filter unit 11 as described above.
  • the valve V1 when one end of the third flow path 30 having the valve V3a is connected to the waste liquid recovery unit, the valve V1 is closed, the valve V3a is opened, and the cleaning liquid is supplied from the first introduction port 12. It may be introduced.
  • the plasma remaining in the filter unit 11 can be collected together with the washing solution in the waste liquid collecting unit connected to the third channel 30 via the third channel 30.
  • the valves V2a and V3a may be opened and the cleaning liquid may be introduced from the second introduction port 22 into the filter unit 11 via the second flow path.
  • the plasma remaining in the filter unit 11 can be collected together with the washing solution in the waste liquid collecting unit connected to the third channel 30 via the third channel 30.
  • a hemolytic agent is introduced into the second flow path 20 from the second introduction port 22.
  • Any hemolytic agent may be used as long as it can destroy blood cells (for example, erythrocytes), and any known hemolytic agent can be used without particular limitation.
  • the hemolytic agent include hypotonic solution, water and the like.
  • the hemolytic agent introduced from the second introduction port 22 reaches the filter unit 11 via the second flow path 20, and the filter unit 11 is in the same direction as the direction in which the blood sample has moved through the filter unit 11 (first direction). To move.
  • blood cells for example, red blood cells
  • the blood cell component released by hemolysis moves through the filter unit 11 together with the hemolytic agent, and moves to the third channel 30 when it reaches the connection with the third channel 30.
  • the fluid control unit causes the hemolytic agent to flow from the second flow path to the filter unit 11 and the third flow from the filter unit 11 to the third flow.
  • the flow of blood cell components to the path 30 may be controlled. By controlling these flows, the time required for the blood cell component to reach the blood cell analyzer 60 can be shortened.
  • the blood cell component moved from the filter unit 11 to the third flow path 30 is analyzed in the blood cell analysis unit 60 connected to the third flow path 30.
  • the blood cell component separation device includes a blood cell collection unit instead of the blood cell analysis unit 60, the blood cell component may be collected by the blood cell collection unit.
  • the hemolysis step may be performed by closing the valves V1, V2a, V2b, and V3a, opening the valve V3b, and introducing the hemolytic agent from the first introduction port 12.
  • the hemolytic agent introduced from the first introduction port 12 hemolyzes the blood cells captured by the filter unit 11, and the released blood cell components are sent to the blood cell analysis unit 60 via the third flow path in the same manner as described above. And move.
  • the plasma and blood cells can be separated and then each collected or analyzed.
  • the blood component separation device includes both the plasma analysis unit 50 and the blood cell analysis unit 60
  • plasma analysis and blood cell analysis can be performed simultaneously with one device, so that blood analysis can be performed quickly and easily. It can be performed. Since the blood cell separation part (filter part) and the plasma analysis part, and the blood cell separation part (filter part) and the blood cell analysis part are connected by the flow path, there is an advantage that there is no risk of contamination.
  • the conventional blood cell separation method cannot prevent the plasma from being mixed into the blood cell fraction, and the analysis result of the blood cell component may become unstable due to the plasma being mixed.
  • the measurement value becomes unstable, and a reliable measurement value cannot be obtained.
  • the plasma remaining on the filter can be removed by the washing liquid, so that the amount of plasma mixed into the blood cell fraction can be reduced. As a result, the influence of plasma in blood cell component analysis can be reduced, and stable blood cell component measurement values can be obtained.
  • the blood component separation device of the present embodiment is not limited to the aspect described above, and each component can be changed as appropriate without departing from the spirit of the present invention.
  • the following modifications 1 to 6 are also within the scope of the blood component separation device of the present embodiment.
  • FIG. 2 is a schematic diagram showing Modification 1 of the blood component separation device of the present embodiment.
  • Blood component separation device 200 has the same configuration as blood component separation device 100 except that it does not have third flow path 30.
  • the side of the second channel 20 opposite to the second inlet 22 with respect to the connection with the first channel is connected to the blood cell analyzer 60.
  • the valve V1 in the hemolysis step of hemolyzing the blood cells captured by the filter unit 11, the valve V1 is closed, the valves V2a and V2b are opened, and the second flow path 20 is opened from the second introduction port 22.
  • Introduce a hemolytic agent The hemolytic agent introduced into the second flow path 20 reaches the filter unit 11 via the second flow path 20, and a direction (second direction) different from the direction (first direction) in which the blood sample moves through the filter unit 11.
  • the filter unit 11 is moved in the direction).
  • the blood cells captured in the second direction in which the hemolytic agent moves are hemolyzed by the hemolytic agent.
  • the blood cell component released by hemolysis is transported from the filter unit 11 to the blood cell analysis unit 60 via the second flow path 20 and analyzed by the blood cell analysis unit 60.
  • the second flow path 20 may include a blood cell collection unit instead of the blood cell analysis unit 60 or in addition to the blood cell analysis unit 60.
  • the second flow path 20 may include a fluid control unit that controls the flow of fluid in the second flow path 20. The same applies to Modifications 4 and 5 described later.
  • FIG. 3 is a schematic diagram showing Modification Example 2 of the blood component separation device of the present embodiment.
  • the blood component separation device 300 has the same configuration as the blood component separation device 100 except that the second flow path 20 and the third flow path 30 do not intersect the first flow path 10.
  • the second flow path 20 and the third flow path 30 are configured to protrude from the filter unit 11, respectively.
  • the valve V1 in the hemolysis step of hemolyzing the blood cells captured by the filter unit 11, the valve V1 is closed, the valves V2a and V3a are opened, and the second flow path 20 is opened from the second introduction port 22. Introduce a hemolytic agent.
  • the hemolyzed hemolytic agent introduced into the second flow path 20 reaches the filter unit 11 via the second flow path 20 and is in the same direction as the direction in which the blood sample has moved through the filter unit 11 (first direction).
  • the filter unit 11 is moved.
  • blood cells captured by the filter are hemolyzed by the hemolytic agent.
  • the blood cell component released by hemolysis moves through the filter unit 11 together with the hemolytic agent, and moves to the third channel 30 when it reaches the connection with the third channel 30. Then, it is carried to the blood cell analyzer 60 via the third flow path 30 and analyzed by the blood cell analyzer 60.
  • FIG. 4 is a schematic diagram showing a third modification of the blood component separation device of the present embodiment.
  • the blood component separation device 400 has the same configuration as the blood component separation device 300 except that the second flow path 20 and the third flow path 30 are arranged in the same direction with respect to the first flow path 10. .
  • the hemolysis process can be performed in the same manner as the blood component separation device 300.
  • FIG. 5 is a schematic diagram showing a fourth modification of the blood component separation device of the present embodiment.
  • the blood component separation device 500 does not have the third flow path 30, and the second flow path 20 does not intersect the first flow path 10.
  • the second flow path 20 is connected to the blood cell analyzer 60.
  • the valve V1 in the hemolysis step of hemolyzing the blood cells captured by the filter unit 11, the valve V1 is closed, the valve V2a is opened, and the first introduction port 12 is connected to the first flow path 10.
  • Introduce hemolytic agent The hemolytic agent introduced into the first channel 10 reaches the filter unit 11 and moves the filter unit 11 in the same direction as the direction in which the blood sample has moved the filter unit 11 (first direction). At this time, blood cells captured by the filter are hemolyzed by the hemolytic agent.
  • the blood cell component released by hemolysis moves through the filter unit 11 together with the hemolytic agent, and moves to the second channel 20 when it reaches the connection with the second channel 20. Then, it is carried to the blood cell analyzer 60 via the second flow path 20 and analyzed in the blood cell analyzer 60.
  • the second flow path 20 may include a blood cell collection unit instead of the blood cell analysis unit 60 or in addition to the blood cell analysis unit 60.
  • the second flow path 20 may include a fluid control unit that controls the flow of fluid in the second flow path 20.
  • FIG. 6 is a schematic diagram showing a fifth modification of the blood component separation device of the present embodiment.
  • the blood component separation device 600 does not have the third flow path 30 and the second flow path 20 does not intersect the first flow path 10.
  • the second flow path 20 is connected to the blood cell analyzer 60.
  • the fourth flow path 40 is connected between the first introduction port 12 of the first flow path 10 and the filter unit 11.
  • the fourth flow path 40 includes a fourth introduction port 42 and a valve V4a.
  • the valve V1 in the hemolysis step of hemolyzing the blood cells captured by the filter unit 11, the valve V1 is closed, the valves V2a and V4a are opened, and the fourth flow path 40 is opened from the fourth inlet 42. Introduce a hemolytic agent.
  • the hemolyzed hemolytic agent introduced into the fourth flow path 40 reaches the first flow path 10 through the fourth flow path 40, moves through the first flow path 10, and reaches the filter unit 11.
  • the hemolytic agent moves through the filter unit 11 in the same direction as the direction in which the blood sample moves through the filter unit 11 (first direction). At this time, blood cells captured by the filter are hemolyzed by the hemolytic agent.
  • the blood cell component released by hemolysis moves through the filter unit 11 together with the hemolytic agent, and moves to the second channel 20 when it reaches the connection with the second channel 20. Then, it is carried to the blood cell analyzer 60 via the second flow path 20 and analyzed in the blood cell analyzer 60.
  • FIG. 7 is a schematic diagram showing Modification 6 of the blood component separation device of the present embodiment.
  • the blood component separation device 700 has a first flow path and a second flow path formed in the plate 70.
  • the first flow path is composed of first flow paths 10a and 10b
  • the second flow path is composed of second flow paths 20a, 20b and 20c.
  • the first flow paths 10a and 10b are connected to each other via a valve V1a.
  • the first flow path 10 a has a first introduction port 12 and a filter unit 11.
  • the first channel 10b includes a pump unit P1 as a channel controller and a plasma analyzer 50.
  • the first flow path 10b is connected to the inlet I1 through the valve V1f.
  • the inlet I1 is connected to a reagent reservoir (not shown) disposed below the plate 70. Therefore, the reagent can be introduced from the inlet I1 into the first flow path 10b by opening the valve V1f.
  • the first flow path 10b is connected to the waste liquid recovery unit W1 via the valve V1c or V1d.
  • the first flow path 10b forms a circulation flow path (first circulation path) by closing the valves V1a, V1c, V1d, and V1f and opening the valves V1b and V1e.
  • the first flow path 10b and the waste liquid collection unit W1 close the valves V1a, V1b, and V1f, and open the valves V1c, V1d, and V1e, thereby allowing fluid to be discharged from the first flow path 10b.
  • a flow path (first discharge path) for discharging to W1 is formed.
  • the second flow paths 20a and 20b are connected to each other via a valve V2e.
  • the second flow paths 20b and 20c are connected to each other via valves V2k and V2m.
  • the second flow path 20 a has a second introduction port 22.
  • the second inlet 22 is connected to a hemolytic agent reservoir (not shown) disposed below the plate 70, and the hemolytic agent can be introduced into the second flow path 20 a from the second inlet 22.
  • the second flow path 20a is connected to the filter portion 11 of the first flow path 10a and intersects the first flow path 10a.
  • Valves V2a and V2b are installed on both sides of the connection portion with the first flow path 10a in the second flow path 20a.
  • the second flow path 20a is connected to the inlet I2 via the valve V2d.
  • the inlet I2 is connected to a reagent reservoir (not shown) disposed below the plate 70. Therefore, the reagent can be introduced from the inlet I2 into the second flow path 20a by opening the valve V2d. Furthermore, the reagent can be introduced into the second flow path 20b by opening the valve V2e. Further, the second flow path 20a is connected to the air inlet A via a valve V2c.
  • the second flow path 20b includes a pump unit P2 as a fluid control unit and a blood cell analysis unit 60.
  • the second flow path 20b is connected to the waste liquid recovery unit W2 via the valve V2h or V2i. Therefore, the waste liquid can be discharged from the second flow path 20b to the waste liquid recovery part W2 by opening the valve V2h or V2i.
  • the second flow path 20c is connected to the inlet I3 through the valve V2n.
  • the inlet I3 is connected to a reagent reservoir (not shown) disposed below the plate 70.
  • the reagent can be introduced from the inlet I3 into the second flow path 20c by opening the valve V2n. Furthermore, the reagent can be introduced into the second flow path 20b by opening the valve V2k or the valve V2m.
  • the second flow path 20c is connected to the waste liquid recovery unit W2 via the valve V2j. Therefore, the waste liquid can be discharged from the second flow path 20c to the waste liquid recovery unit W2 by opening the valve V2j.
  • the second flow path 20b forms a circulation flow path (second circulation path) by closing the valves V2e, V2h, V2i, V2k, V2m and opening the valves V2f, V2g, V2l.
  • the second flow paths 20b and 20c are configured so that the valves V2e, V2h, V2i, V2j, V2l, and V2n are closed, and the valves V2f, V2g, V2k, and V2m are opened, so that the circulation flow path (third (Circulation path) is formed.
  • the second flow path 20b and the waste liquid collection unit W2 close the valves V2e, V2g, V2k, and V2m and open the valves V2f, V2h, V2i, and V2l, thereby allowing fluid to flow into the second flow path 20b.
  • a flow path (second discharge path) for discharging from the waste liquid to the waste liquid recovery unit W2 is formed.
  • the second flow paths 20b and 20c and the waste liquid recovery unit W2 close the valves V2e, V2g, V2i, V2k, V2l, and V2n and open the valves V2f, V2h, V2j, and V2m,
  • a flow path (third discharge path) for discharging the fluid from the second flow paths 20b and 20c to the waste liquid recovery unit W2 is formed.
  • the pump parts P1 and P2 are composed of three valves.
  • the valve include a diaphragm valve including a diaphragm member, and examples of the diaphragm member include an elastomer material.
  • FIGS. 8A and 8B are cross-sectional views for explaining an example of the structure of the diaphragm valve.
  • 8A shows the opened state of the diaphragm valve 800
  • FIG. 8B shows the closed state of the diaphragm valve 800.
  • the diaphragm valve 800 includes a first substrate 310, a diaphragm member 330 made of an elastomer material, and a second substrate 320.
  • the second substrate 320 and the diaphragm member 330 are bonded in close contact.
  • the space between the first substrate 310 and the diaphragm member 330 forms a flow path 315 through which a fluid flows.
  • a through hole 340 is provided in part of the second substrate 320. Further, the diaphragm member 330 is exposed in the through hole 340.
  • the diaphragm valve 800 is arranged in the flow path 315 (the first flow path 10b or the second flow path 20b in the blood component separation device 700), and adjusts the flow of fluid inside the flow path 315.
  • a convex portion is formed in the region of the first substrate 310 facing the through hole 340. 311 may be formed.
  • valve control fluid examples include N2 gas, gas such as air, and liquid such as water and oil.
  • the fluid for valve control can be supplied by, for example, a tube connected to the through hole 340.
  • the elastomer material forming the diaphragm member 330 is not particularly limited as long as it is a material that can be deformed in the axial direction of the through hole 340 in accordance with a change in pressure inside the through hole 340.
  • PDMS polydimethylsiloxane
  • Silicone elastomers such as polymethylphenylsiloxane and polydiphenylsiloxane.
  • a pump can be formed by three or more valves, that is, by arranging three or more valves.
  • FIGS. 9A to 9D are cross-sectional views illustrating the operation of an example of a pump including three diaphragm valves 800a, 800b, and 800c.
  • valve 800a is controlled to be closed, and the valves 800b and 800c are left open. As a result, the fluid flow inside the flow path 315 is blocked by the valve 800a.
  • valves 800a and 800b are controlled to be closed, and the valve 800c is left open.
  • the diaphragm member 330 is deformed, so that the fluid existing around the valve 800b is pushed away.
  • the valve 800a is in the closed state, the displaced fluid moves to the right in the direction indicated by the arrow in FIG. 9C, that is, FIG. 9C. As a result, the fluid flows in the direction indicated by the arrow.
  • valves 800b and 800c are controlled to be closed.
  • the diaphragm member 330 is deformed, so that the fluid existing around the valve 800c is pushed away.
  • the valve 800a since the valve 800a is in the closed state, the displaced fluid moves to the right side in the direction indicated by the arrow in FIG. 9D, that is, in FIG. 9D.
  • the valve 800a may be controlled to an open state as shown in FIG. 9D, or may be maintained in a closed state.
  • valves 800a, 800b and 800c are all controlled to be opened.
  • the fluid inside the flow path 315 may continue to move to the right as viewed in FIG. 9A due to inertia.
  • the flow of fluid inside the flow path 315 can be controlled by repeating the above steps.
  • the above process is an example of a method for controlling a pump including three valves, and the method for controlling a pump including three valves is not limited thereto.
  • the flow of the fluid inside the flow path 315 can be controlled in the opposite direction to that described above by reversing the timing of opening and closing the valves 800a and 800c. It is also possible to control the flow rate by adjusting the cycle in which the operations in FIGS. 9A to 9D are repeated to form a pulsed minute solution flow.
  • the flow velocity can also be controlled by adjusting the pressure of the gas driving the valves 800a to 800c and the diameter of the valve.
  • the structure of the diaphragm valve is not limited to that described above.
  • a diaphragm valve a cylindrical structure having an outer cylinder part and an inner cylinder part described in International Publication No. 2016/006615, and a thin film part arranged to cover one end of the inner cylinder part
  • a valve provided with a diaphragm member having a circumference of the thin film portion and an anchor portion closely attached along the inner wall of the outer cylinder portion and the outer wall of the inner cylinder portion may be used.
  • other usable valves include, for example, a two-color molded valve obtained by continuously molding a resin portion and an elastomer portion using two molds. Illustrated.
  • the two-color molded valve has advantages that the time required for production is short and the adhesiveness between the resin and the elastomer is high.
  • the substrate 909 includes a recess (eg, a flow path) 940A formed on a lower surface (one surface) 909a, a bottom of the recess 940A (eg, an upper side of the recess 90A in FIG. 10), and the substrate 909. And an opening 952 opening (penetrating) in the upper surface (other surface) 909b.
  • a valve driven unit 970 is provided in the opening 952.
  • the valve driven part 970 is made of the same soft material as the valve part 950 described above, and includes a valve part (deformation part) 971 and a cylinder part (connection part) 973.
  • the valve portion 971 closes the lower surface 909 a side of the substrate 909 in the opening 952.
  • the tubular portion 973 is formed of a single member with the valve portion 971, is provided along the inner peripheral surface of the opening portion 952, and is integrally connected to the valve portion 971 at the lower end.
  • the inner space of the cylinder portion 973 is closed at the lower end by the valve portion 971 and forms an opening 970a having an upper end opened.
  • a fluid eg, a solution containing a sample substance, a cleaning liquid, etc.
  • the lower surface 909a of the substrate 909 is joined to the upper surface 908b of the lower plate 908.
  • a curved surface (eg, hemispherical) concave surface 980 is formed on the upper surface 908b at a position facing the depression 940A.
  • the valve driven unit 970 having the above-described configuration is configured such that, for example, when a downward force (eg, air pressure, hydraulic pressure, mechanical force, etc.) is applied to the valve unit 971 through the opening 970a,
  • a downward force eg, air pressure, hydraulic pressure, mechanical force, etc.
  • the open / close state of the flow path eg, the depression 940A
  • the valve portion 971 is deformed and bent toward the recess 940 ⁇ / b> A and contacts the concave surface 980 to close the flow path (e.g., the recess 940 ⁇ / b> A) (the valve is closed).
  • valve driven portion 970 is released from the downward force applied to the valve portion 971, so that the deformation (eg, bending) of the valve portion 971 is eliminated and the flow path ( For example, the recess 940A) is opened (the valve is open).
  • the above-described two-color molded valve can be manufactured, for example, by the method described in International Publication No. 2018/012429.
  • known ones such as those described in International Publication No. 2018/012429 can be used without particular limitation.
  • the valves V1a, V1b, and V1e are opened, and the other valves are closed, and a blood sample (eg, a whole blood sample or the like) is introduced from the first inlet 12 into the first flow path 10a.
  • a blood sample eg, a whole blood sample or the like
  • the blood sample introduced into the first flow path 10a reaches the filter unit 11, and moves the filter unit 11 in the direction of the valve V1a (first direction). At this time, blood cells in the blood sample are captured by the filter.
  • most of the plasma passes through the filter unit 11 and reaches the first flow path 10b.
  • the valve V1a is closed and the pump unit P1 is operated as appropriate, the plasma that has reached the first flow path 10b can be circulated through the first circulation path including the first flow path 10b.
  • a reagent for plasma analysis is introduced from the inlet I1, and circulated through the first circulation path to be mixed with plasma.
  • the plasma analysis unit 50 can perform plasma analysis while circulating the plasma in the first circulation path.
  • the fluid circulating in the first circulation path can be discharged to the waste liquid recovery unit W1 through the first discharge path with the valves V1b and V1f being closed and the valves V1c, V1d and V1e being opened as necessary. .
  • valves V1a, V1c, V1d, and V1e are opened, the other valves are closed, and the cleaning liquid is introduced from the first introduction port 12 into the first flow path 10a.
  • the cleaning liquid introduced into the first flow path 10a reaches the filter unit 11, and moves the filter unit 11 in the valve V1a direction (first direction).
  • the plasma remaining on the filter moves in the first direction together with the washing liquid, and is introduced into the first flow path 10b through the valve V1a.
  • the washing liquid containing plasma introduced into the first flow path 10b can be discharged to the waste liquid collecting part W1 through the first discharge path with the valves 1b and V1f closed and the valves V1c, V1d and V1e opened. .
  • valves V2a, V2b, V2e, V2f, V2g, V2l are opened, the other valves are closed, and the hemolytic agent is introduced from the second inlet 22 into the second flow path 20a.
  • the hemolytic agent introduced into the second flow path 20a reaches the filter unit 11 and moves the filter unit 11 in the valve V2b direction (second direction).
  • the blood cells captured by the filter are hemolyzed by the hemolytic agent.
  • the blood cell component released by hemolysis moves in the second flow path 20a along with the hemolytic agent in the axial direction, and is introduced from the valve V2b to the second flow path 20b via the valve V2e.
  • valve V2b is closed, the valve V2c is opened, and air is blown into the second flow path 20a from the air inlet A. It can guide to the flow path 20b.
  • the blood cell component introduced into the second flow path 20b can be circulated through the second circulation path including the second flow path 20b by closing the valve V2e and appropriately operating the pump part P2.
  • a reagent for blood cell analysis is introduced from inlet I2, and circulated through the second circulation path to be mixed with blood cell components.
  • a reagent for blood cell analysis is introduced from the inlet I3 and circulated through the third circulation path including the second flow paths 20b and 20c to be mixed with the blood cell component.
  • the blood cell analysis unit 60 can perform blood cell analysis while circulating the blood cell component in the second circulation path or the third circulation path.
  • the fluid circulating through the second circulation path or the third circulation path can be discharged to the waste liquid recovery unit W2 through the second discharge path or the third discharge path as necessary.
  • the present invention provides a method for separating blood components using the blood component separation device of the above embodiment.
  • the method of this embodiment includes (a) introducing a blood sample from the first introduction port into the first flow path, and causing the filter to capture blood cells in the blood sample; and (b) the first A hemolysis step of introducing a hemolytic agent from the introduction port or the second introduction port and hemolyzing the blood cells in the filter.
  • the blood component separation method of the present embodiment can be performed in the same manner as the method exemplified in “(Usage method)” described in the above “[Blood component separation device]”.
  • the cleaning liquid is supplied from the first introduction port or the second introduction port.
  • the present invention provides a method for analyzing blood components using the blood component separation device of the above embodiment.
  • the method of this embodiment includes (a) introducing a blood sample from the first introduction port into the first flow path, and causing the filter to capture blood cells in the blood sample; and (b) the step ( After a), a step of introducing a washing liquid into the first flow path from the first introduction port or the second introduction port to remove plasma in the filter, and (c) after the step (b) Introducing a hemolytic agent from the first inlet or the second inlet and hemolyzing the blood cells in the filter; (d) analyzing the blood cells hemolyzed in the step (c); including.
  • the blood component analysis method of the present embodiment can be performed in the same manner as the method exemplified in “(Usage method)” described in “[Blood component separation device]” above.
  • the blood cell analysis unit 60 can analyze the blood cell component in the step (d).
  • the method of the present embodiment further includes (d) a step of analyzing the plasma that has passed through the filter after the step (a) or the step (b). May be included.
  • a blood component separation device including the plasma analysis unit 50 the plasma analysis can be performed by the plasma analysis unit 50.
  • the present invention provides a method for analyzing hemoglobin A1c.
  • the method of this embodiment includes (a) a step of capturing blood cells in a blood sample with a filter that separates blood cells and plasma, and (b) a washing liquid is passed through the filter after the step (a), Removing the plasma in the filter; (c) after the step (b), introducing a hemolytic agent into the filter and hemolyzing the blood cells in the filter; and (d) in the step (c) Analyzing hemoglobin A1c in the hemolyzed blood cells.
  • the method of the present embodiment can be performed in the same manner as the method exemplified in “(Usage method)” described in “[Blood component separation device]” above. Further, the method of this embodiment may be performed using a column or the like equipped with a blood cell separation filter without using the blood component separation device of the above embodiment.
  • HbA1c can be performed using a known HbA1c measurement method.
  • a method for measuring hemoglobin A1c include latex agglutination.
  • latex agglutination method latex particles are adsorbed with HbA1c (adsorption reaction), reacted with an anti-HbA1c antibody (mouse IgG or the like), and further reacted with a secondary antibody (anti-mouse IgG antibody or the like).
  • HbA1c is cross-linked by the anti-HbA1c antibody and the secondary antibody, and latex particles aggregate (aggregation reaction). The higher the HbA1c concentration, the greater the amount of latex particles aggregated.
  • Non-aggregated latex particles do not reflect light, but when aggregated, light is reflected, so the amount of transmitted light varies depending on the amount of latex particles aggregated. Therefore, the HbA1c concentration can be measured by measuring the absorbance after the aggregation reaction. As an example, the HbA1c concentration can be calculated from a value obtained by subtracting the absorbance at 800 nm from the absorbance at 660 nm.
  • the measured value of HbA1c becomes unstable when plasma is present, and a highly reliable measured value cannot be obtained.
  • blood cells are captured by the filter, and then the filter is washed with a washing solution to remove plasma in the filter. Thereby, the amount of plasma mixed in the blood cell component hemolyzed by the hemolytic agent can be greatly reduced. Therefore, a highly reliable HbA1c measurement value can be obtained.
  • HbA1c concentration 6.1%, HbA1c concentration 10%; hemoglobin A1c cut-off test certified reference material, laboratory medicine reference material mechanism Human plasma was added so as to be 60% (v / v).
  • the HbA1c concentration of the HbA1c standard test reagent to which human plasma was added was measured by a latex agglutination method using Lapidia (registered trademark) Auto HbA1c-L (Fujirebio).
  • the plasma content in the sample is desirably 15% (v / v) or less.
  • Cyra-added rabbit whole blood was prepared by adding 1 ⁇ L of Cy5 and mixing it with 1000 ⁇ L of rabbit whole blood to trace plasma components.
  • the Cy5-added rabbit whole blood sample was centrifuged (centrifugal force (1000 ⁇ g), 5 minutes) to separate a blood cell fraction and a plasma fraction.
  • a dilution series of the blood cell fraction and the plasma fraction was prepared, and a calibration curve for the amount of hemoglobin and the amount of Cy5 was prepared using each dilution series.
  • the blood cell separation of the Cy5-added rabbit whole blood sample was performed using a blood component separation device having the structure shown in FIG.
  • the ports a and c of the second flow path are closed, 100 ⁇ L of hypotonic solution is introduced from the port d of the third flow path, the blood cell fraction captured by the filter is dissolved, and hemolysis is performed from the port b.
  • the collected blood cell fraction was collected.
  • the collected blood cell fraction was measured for hemoglobin absorbance and Cy5 fluorescence, and the plasma content in the blood cell fraction was calculated from the calibration curve prepared above.
  • FIG. 16 is a photograph of each blood component separation device after the blood cell fraction was collected after washing the filter with each PBS amount. Comparing the color of the liquid immediately after passing through the filter (dotted oval), it was qualitatively shown that the blue component of Cy5 becomes lighter as the amount of cleaning liquid increases. When the blue portion of Cy5 was plasma, it was considered that most of the plasma in the filter was removed with a washing liquid volume of 25 ⁇ L.
  • Example 5 Reproducibility evaluation of measured values of HbA1c (Example 1) Using a blood component separation device having the structure shown in FIG. 11, blood cell separation of human refrigerated blood (normal human whole blood / type O, Kojin Bio) was performed. From the inlet, 10 ⁇ L of human chilled blood was introduced into the first flow path, negative pressure was applied at 10 kPa for 2 minutes from the opposite side of the inlet, and the human chilled blood was passed through the filter. Next, PBS 25 ⁇ L, 25 ⁇ L, or 30 ⁇ L was introduced into the first channel from the inlet (10 kPa negative pressure: 2 minutes), and the filter was washed.
  • human refrigerated blood normal human whole blood / type O, Kojin Bio
  • the port a of the second flow path and the port d of the third flow path are closed, 100 ⁇ L of hypotonic solution is introduced from the port c of the second flow path, and the blood cell fraction captured by the filter is dissolved.
  • the hemolyzed blood cell fraction was collected from port b of the third flow path.
  • a latex agglutination method using Lapidia (registered trademark) Auto HbA1c-L was performed using 5 ⁇ L of the hemolyzed blood collected as described above, and absorbance at 660 nm and 800 nm was measured. From the measured absorbance, the HbAc1 concentration and the coefficient of variation (CV) were calculated.
  • Example 1 The results of Example 1 and Comparative Examples 1 and 2 are shown in FIG. In Example 1, as compared with Comparative Examples 1 and 2, it was confirmed that the coefficient of variation (CV) was small and measurement with high reproducibility was possible.
  • CV coefficient of variation
  • the port a of the second channel and the port d of the third channel are closed, 50 ⁇ L of hypotonic solution is introduced from the port c of the second channel, and the blood cell fraction captured by the filter is dissolved.
  • the hemolyzed blood cell fraction was collected from port b of the third flow path.
  • the recovery of the hemolyzed blood was finished.
  • a latex agglutination method using Lapidia (registered trademark) Auto HbA1c-L was performed, and absorbance at 660 nm and 800 nm was measured.
  • the coefficient of variation (CV) was calculated from the measured absorbance.
  • the blood cell fraction of human whole blood was separated by centrifugal separation (centrifugal force (1000 ⁇ g), 5 minutes), and the absorbance at 660 nm and 800 nm was measured in the same manner.
  • HbAc1 concentration of human whole blood was measured using Affinion (registered trademark) HbAic (Alere)
  • the HbAc1 concentration was 5.06%.
  • Results are shown in FIG. In FIG. 18, a standard specimen (HbA1c concentration 6.1%, HbA1c concentration 10%; hemoglobin A1c cut-off test certified reference material, laboratory medicine reference material mechanism) was measured using Rapidia (registered trademark) Auto HbA1c-L. The results are also shown.
  • the measured HbA1c value equivalent to the blood cell fraction obtained by the centrifugation method was obtained.
  • the coefficient of variation (CV) was small compared with the centrifugation method.
  • the blood cell fraction separated using the blood component separation device had a lower measured value by the latex agglutination method than the standard specimen.
  • the HbA1c concentration of normal human whole blood is 6% or less. Therefore, the reliability of the measured value by this method was shown by comparison with the measured value of the standard specimen (HbA1c concentration 6.1%, HbA1c concentration 10%).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un dispositif de séparation de constituants du sang qui comprend un premier canal d'écoulement (10) pourvu d'un premier orifice d'introduction (12) et d'une partie filtre (11) dans laquelle est installé un filtre permettant de séparer les cellules sanguines et le plasma sanguin, et un second canal d'écoulement (20) relié à la partie filtre du premier canal d'écoulement.
PCT/JP2018/017040 2018-04-26 2018-04-26 Dispositif de séparation de constituants du sang, procédé de séparation de constituants du sang et procédé d'analyse de constituants du sang WO2019207724A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/JP2018/017040 WO2019207724A1 (fr) 2018-04-26 2018-04-26 Dispositif de séparation de constituants du sang, procédé de séparation de constituants du sang et procédé d'analyse de constituants du sang
JP2020515400A JP6939988B2 (ja) 2018-04-26 2018-04-26 血液成分分離デバイス、血液成分分離方法、及び血液成分分析方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2018/017040 WO2019207724A1 (fr) 2018-04-26 2018-04-26 Dispositif de séparation de constituants du sang, procédé de séparation de constituants du sang et procédé d'analyse de constituants du sang

Publications (1)

Publication Number Publication Date
WO2019207724A1 true WO2019207724A1 (fr) 2019-10-31

Family

ID=68293924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/017040 WO2019207724A1 (fr) 2018-04-26 2018-04-26 Dispositif de séparation de constituants du sang, procédé de séparation de constituants du sang et procédé d'analyse de constituants du sang

Country Status (2)

Country Link
JP (1) JP6939988B2 (fr)
WO (1) WO2019207724A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022220505A1 (fr) * 2021-04-14 2022-10-20 계명대학교 산학협력단 Système de mesure de glucose et d'hémoglobine glyquée
WO2023127707A1 (fr) * 2021-12-29 2023-07-06 株式会社Provigate Procédé de mesure d'élément de composant d'hémocyte et d'élément de composant non-hémocyte dans une quantité infime de sang, dispositif et cartouche de pipette

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54122713A (en) * 1978-03-17 1979-09-22 Asahi Chem Ind Co Ltd Separation of leukocyte
JP2006501449A (ja) * 2002-09-27 2006-01-12 ザ ジェネラル ホスピタル コーポレーション 細胞分離のためのマイクロ流体デバイスおよびその使用
JP2012088089A (ja) * 2010-10-15 2012-05-10 Nanbu Plastics Co Ltd 臨床検査キットおよび血液の検査方法
WO2014112318A1 (fr) * 2013-01-16 2014-07-24 富士レビオ株式会社 Procédé de dosage immunologique de l'hémoglobine a1c dans un échantillon

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54122713A (en) * 1978-03-17 1979-09-22 Asahi Chem Ind Co Ltd Separation of leukocyte
JP2006501449A (ja) * 2002-09-27 2006-01-12 ザ ジェネラル ホスピタル コーポレーション 細胞分離のためのマイクロ流体デバイスおよびその使用
JP2012088089A (ja) * 2010-10-15 2012-05-10 Nanbu Plastics Co Ltd 臨床検査キットおよび血液の検査方法
WO2014112318A1 (fr) * 2013-01-16 2014-07-24 富士レビオ株式会社 Procédé de dosage immunologique de l'hémoglobine a1c dans un échantillon

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022220505A1 (fr) * 2021-04-14 2022-10-20 계명대학교 산학협력단 Système de mesure de glucose et d'hémoglobine glyquée
WO2023127707A1 (fr) * 2021-12-29 2023-07-06 株式会社Provigate Procédé de mesure d'élément de composant d'hémocyte et d'élément de composant non-hémocyte dans une quantité infime de sang, dispositif et cartouche de pipette

Also Published As

Publication number Publication date
JPWO2019207724A1 (ja) 2021-01-14
JP6939988B2 (ja) 2021-09-22

Similar Documents

Publication Publication Date Title
US10967374B2 (en) Methods of analyzing biological samples using a fluidic cartridge
US9767343B1 (en) Automated microscopic cell analysis
CA2456695C (fr) Element de test diagnostique et methode pour analyses du sang
US8980635B2 (en) Disposable cartridge for fluid analysis
US9157903B2 (en) Microfluidic separation of plasma for colormetric assay
US9199233B2 (en) Biologic fluid analysis cartridge with deflecting top panel
US8741233B2 (en) Disposable cartridge for fluid analysis
US8741234B2 (en) Disposable cartridge for fluid analysis
US8741235B2 (en) Two step sample loading of a fluid analysis cartridge
US9199236B2 (en) Biologic fluid sample analysis cartridge with sample collection port
US20070042427A1 (en) Microfluidic laminar flow detection strip
WO2010140706A1 (fr) Systèmes d'opérations biologiques et industrielles
US8470259B2 (en) Method and device for particle removal and droplet preparation for qualitative and quantitative bioanalysis
US20160008813A1 (en) Microfluidic distributing device
WO2019207724A1 (fr) Dispositif de séparation de constituants du sang, procédé de séparation de constituants du sang et procédé d'analyse de constituants du sang
Gao et al. A simple and rapid method for blood plasma separation driven by capillary force with an application in protein detection
KR20230021032A (ko) 생물학적 유체 분리 장치
CN113302492A (zh) 用于分析流体样品的系统和方法
EP3160647B1 (fr) Cartouche d'essai microfluidique sans commande de fluide active
US20210291159A1 (en) Integrated system for sampling and processing a liquid suspension
EP2090365A1 (fr) Analyse cellulaire et protéinique combinée sur un substrat
US20150086970A1 (en) Whole Blood Analytic Device And Method Therefor
US11859734B2 (en) Valve for microfluidic device
US20220111383A1 (en) In Vitro Diagnostic Device with Integrated Plasma Separator
TWM636774U (zh) 微流道晶片

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18916006

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020515400

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18916006

Country of ref document: EP

Kind code of ref document: A1